Eli Lilly Inks Deal to Acquire Nexus Manufacturing Plant in Wisconsin as Mounjaro and Zepbound Shortages Drag On

As doctors and patients in the U.S. grapple with widening shortages of the popular diabetes therapy Mounjaro and its obesity counterpart Zepbound, the maker of the tirzepatide drugs, Eli Lilly, is forging ahead on its quest to expand capacity for its injectable medicines. Lilly is paying an undisclosed sum to acquire Nexus Pharmaceuticals’ injectable production facility in Pleasant Prairie, Wisconsin, in a bid to further expand its manufacturing network and respond to “increased demand for the company’s medicines,” according to a press release.

Read the full article: Eli Lilly Inks Deal to Acquire Nexus Manufacturing Plant in Wisconsin as Mounjaro and Zepbound Shortages Drag On //

Source: https://www.fiercepharma.com/pharma/eli-lilly-inks-deal-acquire-nexus-manufacturing-plant-wi-mounjaro-and-zepbound-shortages

Leave a Comment

Your email address will not be published.

Scroll to Top